TW202612704A - 用於治療cns病症之組合物及方法 - Google Patents

用於治療cns病症之組合物及方法

Info

Publication number
TW202612704A
TW202612704A TW114119429A TW114119429A TW202612704A TW 202612704 A TW202612704 A TW 202612704A TW 114119429 A TW114119429 A TW 114119429A TW 114119429 A TW114119429 A TW 114119429A TW 202612704 A TW202612704 A TW 202612704A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
group
alkyl
compound
Prior art date
Application number
TW114119429A
Other languages
English (en)
Chinese (zh)
Inventor
艾伯特 J 羅比喬德
法藍西司科 G 薩突羅
佩拉杜 馬利亞 耶稣 巴蘭可
丹尼爾 拉
柏伊德 L 哈里森
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202612704A publication Critical patent/TW202612704A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/006—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by sulfur as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TW114119429A 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法 TW202612704A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862617134P 2018-01-12 2018-01-12
US201862616768P 2018-01-12 2018-01-12
US62/616,768 2018-01-12
US62/617,134 2018-01-12
US201862728514P 2018-09-07 2018-09-07
US62/728,514 2018-09-07

Publications (1)

Publication Number Publication Date
TW202612704A true TW202612704A (zh) 2026-04-01

Family

ID=65324563

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114119429A TW202612704A (zh) 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法
TW108101261A TW201930269A (zh) 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108101261A TW201930269A (zh) 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法

Country Status (6)

Country Link
US (3) US11718642B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706761A3 (cg-RX-API-DMAC7.html)
JP (3) JP7538040B2 (cg-RX-API-DMAC7.html)
MA (1) MA51568A (cg-RX-API-DMAC7.html)
TW (2) TW202612704A (cg-RX-API-DMAC7.html)
WO (1) WO2019140272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230018765A1 (en) * 2019-12-05 2023-01-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN111233815B (zh) * 2020-01-21 2022-10-14 上海应用技术大学 一种异阿根廷蚁素的制备方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Gabaaレセプター複合体と相互作用させるための化合物
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
PT837874E (pt) 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN109503694A (zh) 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
CN113272315B (zh) 2018-12-26 2023-08-08 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
JP2025106370A (ja) 2025-07-15
JP7817214B2 (ja) 2026-02-18
EP3737687B1 (en) 2025-10-22
JP2023145726A (ja) 2023-10-11
WO2019140272A1 (en) 2019-07-18
US20260078143A1 (en) 2026-03-19
US20240150393A1 (en) 2024-05-09
TW201930269A (zh) 2019-08-01
JP2021510695A (ja) 2021-04-30
US12421275B2 (en) 2025-09-23
EP3737687A1 (en) 2020-11-18
US20200354399A1 (en) 2020-11-12
MA51568A (fr) 2021-04-21
EP4706761A3 (en) 2026-05-06
EP4706761A2 (en) 2026-03-11
US11718642B2 (en) 2023-08-08
JP7538040B2 (ja) 2024-08-21

Similar Documents

Publication Publication Date Title
JP7817214B2 (ja) CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
JP7611186B2 (ja) C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
TWI924370B (zh) 神經活性類固醇及其使用方法
JP7817179B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7569412B2 (ja) CNS障害を処置するためのジュウテリウム化された21-[4-シアノ-ピラゾール-1-イル]-19-ノル-プレガン-3.α-オール-20-オン誘導体
TWI835765B (zh) 用於治療cns病症之組合物及方法
JP7754725B2 (ja) Cns障害を治療するための組成物及び方法
JP7670632B2 (ja) Cns障害を治療するための組成物及び方法
TWI848034B (zh) 神經活性類固醇及其組合物
TWI886813B (zh) 神經活性類固醇及其使用方法
JP7787635B2 (ja) Cns障害を治療するための組成物及び方法
JP7534291B2 (ja) 9(11)-不飽和神経刺激性ステロイド及びそれらの使用方法
TW202233198A (zh) 神經活性類固醇及其組合物
JP2022534424A (ja) 神経刺激性ステロイド及びその組成物
WO2016123056A1 (en) Compositions and methods for treating cns disorders
BR122024007325A2 (pt) Compostos esteroides neuroativos de 3-alfa-hidróxi-17-beta-amida, suas composições farmacêuticas e seus usos